TNG462 has strong efficacy across a panelof both cell-derived and patient-derived xenograft models includingthose representing pancreatic, nonsmall cell lung, mesothelioma, andbladder cancer, which all have a high prevalence of MTAP deletion, and demonstrates extended PD hold in vivo, with levels of SDMA below assay detection limit up to 72 h post-lastdose. This evidence concerns the gene MTAP and cancer.